Mochida Pharmaceutical Co., Ltd.
Notice Regarding Revision of Earnings Guidance
For the fiscal year ending March 2026, net sales have been upwardly revised to JPY 115.5 billion (4.5% increase from previous forecast), operating income to JPY 9.5 billion (35.7% increase), and net income attributable to owners of parent to JPY 8.4 billion (55.6% increase).
Key Figures
- Net Sales: 115,500 million yen (4.5% increase from previous forecast)
- Operating Income: 9,500 million yen (35.7% increase from previous forecast)
- Net Income Attributable to Owners of Parent: 8,400 million yen (55.6% increase from previous forecast)
AI要約
Overview of Revision of Earnings Guidance
Mochida Pharmaceutical Co., Ltd. has revised its consolidated earnings forecast for the fiscal year ending March 2026. Net sales are projected at JPY 115.5 billion, operating income at JPY 9.5 billion, ordinary income at JPY 11 billion, and net income attributable to owners of parent at JPY 8.4 billion, all exceeding the previously announced forecast. Net sales have been upwardly revised by 4.5%, operating income by 35.7%, ordinary income by 46.7%, and net income by 55.6% compared to the prior forecast.
Reasons for Revision and Future Outlook
The main reasons for the revision are steady performance in the pharmaceutical-related business and increased equity-method investment income. These factors have resulted in net sales and earnings projections exceeding the previous forecast. However, it is also noted that these forecasts are based on information available at the time of announcement and actual results may differ due to various future factors.
